Pituitary volumes were measured in 55 first-episode schizophrenia patients at a baseline timepoint with 38 receiving a followup scan after antipsychotic treatment. Fifty-nine healthy volunteers had baseline scans with 34 receiving a followup scan. There were no baseline group differences in pituitary volumes or changes in volume following antipsychotic treatment.
Introduction
The pituitary gland is part of the hypothalamic-pituitary-adrenal (HPA) axis, one of the primary biological systems that mediate the experience of stress (De Groot and Harris, 1950; Sam and Frohman, 2008) . Abnormalities in HPA axis functioning have been implicated in schizophrenia and related psychotic disorders (Walker and Diforio, 1997) , with multiple studies reporting HPA axis hyperactivity in the onset and exacerbation of psychotic symptoms (Muck-Seler et al., 1999; Ryan et al., 2004 ). Studies also demonstrate higher levels of adrenocorticotropic hormone (ACTH) and cortisol among individuals experiencing their first psychotic episode (Ryan et al., 2003 (Ryan et al., , 2004 Walsh et al., 2005) .
Magnetic resonance imaging (MRI) studies investigating the pituitary in schizophrenia and related psychotic disorders have yielded mixed findings. Some groups reported larger (Pariante et al., 2004; Pariante et al., 2005; Takahashi et al., 2009 ) or smaller (Pariante et al., 2004 Upadhyaya et al., 2007) pituitary volume in patients compared to healthy controls, although two studies reported no group differences (Tournikioti et al., 2007; Nicolo et al., 2010) . The use of antipsychotic medications could influence pituitary volume, possibly via the inhibition of corticotrophin releasing-hormone (CRH) gene activity (BastaKaim et al., 2006) or the stimulation of prolactin-secreting cells (Meltzer and Fang, 1976; Gruen et al., 1978) . Several magnetic resonance imaging (MRI) studies have supported the possibility of pituitary volume changes in association with antipsychotic treatment, although findings have been inconsistent regarding the direction of changes (Pariante et al., 2005; MacMaster et al., 2007a; Nicolo et al., 2010) . Such inconsistencies may be due to the heterogeneity of the samples including differences in prior antipsychotic drug exposure.
The goal of the current study was to compare pituitary volumes between patients experiencing a first episode of schizophrenia with minimal or no prior antipsychotic drug exposure to healthy volunteers and to investigate possible changes in pituitary volume following antipsychotic treatment.
Methods

Subjects
The 55 patients in this study were participating in clinical trials investigating antipsychotic drug efficacy. Twenty-eight of the 55 patients were antipsychotic drug-naïve at the time of the baseline scan whereas 23 had a mean exposure of 8 days (S.D. = 7) to typical or atypical antipsychotics prior to the baseline scan. Medication history prior to the baseline scan was unavailable for four patients. Thirty-eight of the 55 patients received followup scans after a median 22 weeks (range 16-169 weeks) of antipsychotic treatment with olanzapine, risperidone, clozapine, prolixin, perphenazine and/or haloperidol. We converted medications received between the two scan timepoints to chlorpromazine equivalents using the approaches described by Woods (2003) and Lehman et al. (2004) . Medication data at the time of the second scan were unavailable for two patients as these patients terminated their clinical trials prior to the second scan. Diagnoses were 
